Shares of Protara Therapeutics Inc. (TARA) are down nearly 32% from their 52-week high of $7.82, recorded last November, and trade around $5.
Protara is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. Its lead drug candidate is TARA-002, which is derived from an inactivated Group A Streptococcus pyogenes bacterium, specifically type 3, strain SU.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com